MARK ZIMMERMAN: Open Payments
NPI 1508842857 · CRANSTON, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$58,029 in 82 payments from 4 companies in 2025. Trend: 2023 $39,910 · 2024 $67,776 · 2025 $58,029
Speaker / faculty: $32,415Consulting: $11,659Travel & lodging: $11,613Food & beverage: $2,343
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 71 | $56,181 |
| Merck Sharp & Dohme LLC | 8 | $1,785 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Novo Nordisk Inc | 1 | $19 |
Products named: CAPLYTA, REXULTI, Wegovy.
Industry payments across RI — which companies pay providers there.
